What Protomer Technologies does

Protomer Technologies is a Pasadena, California-based biotechnology company engineering next-generation responsive biotherapeutics for metabolic disease, with a primary focus on glucose-responsive insulin receptor agonists for type 1 and insulin-dependent diabetes. The company was founded in 2015 by Caltech alumni and faculty and built its core asset — the Molecular Evolution of Peptide Sensors (MEPS) platform — a proprietary chemical-biology technology that uses synthetic libraries of naturally occurring, non-canonical, and chemically modified monomer building blocks to create conditionally active binding moieties. These moieties enable therapeutic peptides and proteins to sense specific molecular signals in the body (such as rising or falling blood glucose) and automatically modulate their activity, representing a fundamentally different mechanism from static biotherapeutics and potentially widening the therapeutic window through demand-responsive dosing. The lead clinical candidate is a glucose-sensing insulin receptor agonist intended to eliminate or reduce the daily burden of finger pricks, injections, and pump calibrations for the roughly 10 million people worldwide living with type 1 diabetes.

Protomer was acquired by Eli Lilly and Company (NYSE: LLY) on July 14, 2021, and now operates as a wholly-owned subsidiary within Lilly Research Labs, retaining startup-style operating autonomy while leveraging Lilly's pharmaceutical development, regulatory, manufacturing, and global commercial infrastructure. The company is pre-commercial and generates no independent product revenue; its value is realized through Lilly's commercialization of any approved therapies derived from the MEPS platform. Distribution, upon regulatory approval, flows through Lilly's global pharmaceutical supply chain serving pharmacies, hospitals, and healthcare providers. Protomer is led by co-founder and CEO Alborz Mahdavi, PhD (Caltech PhD '15) and COO Jack Steele, with a small team of approximately 10 PhD scientists and operations staff across chemistry, biology, and biochemistry functions. Pre-acquisition capital included an investment from the JDRF T1D Fund in November 2020. Customer concentration is effectively a single parent: Eli Lilly is both the controlling shareholder and the sole channel to market for any Protomer-derived therapy.

Name

Protomer Technologies

Legal name

Protomer Technologies Inc.

Website

https://protomer.com

Company type

Private

Founded year

2015

Operating status

Acquired

Headcount range

1–10 employees

Short description

Protomer Technologies is a Pasadena-based biotech developing glucose-responsive insulin and other responsive biotherapeutics via its proprietary MEPS peptide-engineering platform. Founded in 2015 and acquired by Eli Lilly in July 2021, it now operates as a wholly-owned subsidiary within Lilly Research Labs targeting diabetes patients.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Metabolic Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Responsive biotherapeutics
• Peptide engineering platform
• Glucose-responsive insulin
• Metabolic disease therapeutics
• Protein engineering platform

Headquarters

HQ city

Pasadena

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Biopharmaceutical Development and Licensing: As a pre-commercial biotech subsidiary of Eli Lilly, Protomer generates value through R&D advancement of therapeutic candidates through clinical development. The company was acquired by Eli Lilly in 2021, and its clinical candidates are now part of Lilly's pipeline. Revenue generation occurs through Lilly's commercialization of approved therapies derived from Protomer's platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Protomer Technologies engineers next-generation responsive biotherapeutics using its proprietary Molecular Evolution of Peptide Sensors (MEPS) platform, a chemical biology-based technology for developing therapeutic peptides and proteins whose activity can be controlled using small molecules. The company's lead therapeutic candidate is a glucose-responsive insulin receptor agonist that senses blood glucose levels and automatically adjusts its activity, intended to improve the daily management of type 1 diabetes.

Product overview

Protomer Technologies operates as a single-product biotech company focused on developing next-generation responsive biotherapeutics. The company leverages its proprietary MEPS (Molecular Evolution of Peptide Sensors) platform to engineer therapeutic peptides and proteins with conditionally active binding properties. Their lead candidate is a glucose-responsive insulin receptor agonist that can sense molecular activators in the body and automatically adjust its activity based on blood glucose levels. The company's clinical candidates, including the glucose-sensing insulin receptor agonist, are now part of Eli Lilly's publicly available pipeline following the 2021 acquisition.

Differentiator

Problem solved

Functional benefit

Products and services

• MEPS Platform (Molecular Evolution of Peptide Sensors) Proprietary chemical biology-based platform that enables the development of therapeutic peptides and proteins with tunable activity that can be controlled using small molecules. The platform incorporates naturally occurring, non-canonical, and chemically modified monomer building blocks to create conditionally active binding moieties, and is the foundational technology used by Protomer and now Eli Lilly to develop responsive biotherapeutics.
• Glucose-Responsive Insulin Receptor Agonist A therapeutic candidate that modulates insulin receptor activity in response to rising and falling blood glucose levels, functioning as an automatic activity adjuster based on sugar levels in the blood. Targeted at patients with type 1 diabetes who require daily insulin management, intended to reduce the burden of finger pricks, injections, and insulin pump applications.

Quantifiable outcome

• Nearly 10 million people around the world living with type 1 diabetes require daily insulin management

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Eli Lilly and CompanycoreStrategic or Co-development Partner · 14 July 2021In July 2021, Eli Lilly and Company acquired Protomer Technologies, making it a wholly-owned subsidiary operating within Lilly Research Labs. The acquisition combined Protomer's proprietary peptide- and protein-engineering platform with Lilly's pharmaceutical development and commercialization capabilities. Protomer maintains its startup agility while leveraging Lilly's global resources and infrastructure.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Sanofi: Sanofi is a major incumbent in diabetes with established insulin and GLP-1 franchises. It is a broad comparable as a large pharmaceutical company with active diabetes pipeline investments that compete with the therapeutic category Protomer is targeting.
• Novo Nordisk: Novo Nordisk is the global market leader in insulin and a dominant player in diabetes care. As the incumbent supplier of modern insulin analogs, it competes with Protomer's lead candidate at the commercial level and has internal R&D efforts in next-generation insulin, including glucose-responsive programs.

Direct peers

• Adocia: Adocia is a French clinical-stage biotech developing glucose-responsive insulin formulations (BioChaperone technology). It is a direct competitor to Protomer in the smart insulin space, targeting the same patient population with a similar therapeutic concept of activity-modulated insulin delivery.
• MannKind Corporation: MannKind develops and commercializes Technosphere inhaled insulin (Afrezza) and endocrine-focused therapies. It is a direct peer as a smaller-cap biotech commercializing alternative insulin delivery technologies for the same diabetes patient population.

Emerging players

• Theradaptive: Theradaptive is a biotech developing engineered protein therapeutics with a focus on targeted delivery. It is an emerging comparable to Protomer in the protein engineering for therapeutic applications space, though it is more focused on regenerative medicine applications.
• Generate Biomedicines: Generate Biomedicines is a generative biology platform using machine learning to design novel protein therapeutics. It is an emerging comparable to Protomer in the engineered therapeutic protein space, although it takes a computational rather than chemical biology approach to programmable biologics.
• Ginkgo Bioworks: Ginkgo Bioworks operates a synthetic biology platform for engineering organisms and proteins. It is an emerging comparable to Protomer's MEPS platform in terms of platform-based protein/molecule engineering, though its primary focus is on cell engineering rather than therapeutic proteins.
• Crinetics Pharmaceuticals: Crinetics Pharmaceuticals develops peptide-based therapeutics targeting endocrine diseases and metabolic disorders. It is an emerging comparable in the therapeutic peptide space, with a similar focus on endocrine/metabolic indications although it focuses on oral small peptides rather than responsive biologic engineering.
• Neoleukin Therapeutics: Neoleukin Therapeutics (now reverted to its prior Aquinox Pharmaceuticals identity) developed computationally designed protein therapeutics. It is an emerging comparable in the engineered/de novo protein therapeutic category that overlaps with Protomer's conditionally active therapeutic approach.
• Fractyl Health: Fractyl Health is a clinical-stage biotech developing therapies for metabolic diseases including type 2 diabetes and obesity. It is an emerging comparable as a smaller metabolic-disease-focused biotech pursuing disease-modifying approaches in the same therapeutic category Protomer targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/protomer-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protomer Technologies